Order Article Reprints

Stuckey R, Segura-Díaz A, Sáez Perdomo MN, Pérez Encinas MM, González San Miguel JD, Florido Y, Sánchez-Sosa S, López-Rodríguez JF, Bilbao-Sieyro C, Gómez-Casares MT on behalf of the Spanish CML Group (GELMC). Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment. Cancers. 2023; 15(13):3384. https://doi.org/10.3390/cancers15133384

Stuckey, Ruth, Adrián Segura-Díaz, María Nieves Sáez Perdomo, Manuel Mateo Pérez Encinas, Jóse David González San Miguel, Yanira Florido, Santiago Sánchez-Sosa, Juan Francisco López-Rodríguez, Cristina Bilbao-Sieyro, and María Teresa Gómez-Casares on behalf of the Spanish CML Group (GELMC). 2023. "Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment" Cancers 15, no. 13: 3384. https://doi.org/10.3390/cancers15133384

Stuckey, R., Segura-Díaz, A., Sáez Perdomo, M. N., Pérez Encinas, M. M., González San Miguel, J. D., Florido, Y., Sánchez-Sosa, S., López-Rodríguez, J. F., Bilbao-Sieyro, C., & Gómez-Casares, M. T., on behalf of the Spanish CML Group (GELMC). (2023). Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment. Cancers, 15(13), 3384. https://doi.org/10.3390/cancers15133384